Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Radioactive Iodine Therapy vs. Antithyroid Medications for Graves’ Disease
source: American Family Physician
year: 2017
authors: Petersen J, Lin KW
summary/abstract:Graves disease is the most common cause of hyperthyroidism in the United States. Although radioactive iodine therapy is the most commonly used treatment for Graves disease in the United States, patients in Europe and Japan are more likely to receive antithyroid medications or surgical thyroidectomy. This Cochrane review compared radioactive iodine therapy with antithyroid medications for quality-of-life outcomes, improvement or prevention of Graves ophthalmopathy, relapse rates, and cost-effectiveness. This review included two randomized controlled trials (RCTs) involving 425 adults with Graves disease across 11 Swedish outpatient care centers. Among these, 221 patients were randomized to methimazole (Tapazole) therapy for 18 months and 204 were randomized to a single dose of radioactive iodine therapy.
The follow-up period ranged from two to 21 years after treatment completion, depending on the observed outcome. Other RCTs were excluded for reasons such as having a follow-up duration of less than two years (four RCTs), including patients who had received other treatment for Graves disease before the study intervention (one RCT), using inadequate randomization (one RCT), and examining other non-Graves thyroid disorders in the same study (one RCT).
organization: Georgetown University Medical Center, USAread more full text
Related Content
-
Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ DiseaseBackground: Definitive treatment of Gra...
-
Impaired Immune Regulation After Radioiodine Therapy for Graves’ Disease and the Protective Effect of Methimaz...Both therapies for Graves' disease (GD),...
-
A Mild Risk of Neonatal Hyperthyroidism Follows Radioactive Iodine Therapy for Graves’ Disease Prior to PregnancyGraves’ disease is an autoimmune condi...
-
Post-Partum and Non-Post-Partum Relapsing Graves’ Hyperthyroidism Display Different Response to Anti-Thyroid D...Design: Graves’ disease (GD) patients...
-
FDA Drug Safety Communication: New Boxed Warning on Severe Liver Injury With PropylthiouracilThe United States Food and Drug Administ...
-
Increased Cancer Incidence After Radioiodine Treatment for HyperthyroidismBackground: Concerns remain about risk ...
-
Cancer Incidence and Mortality After Radioiodine Treatment for Hyperthyroidism: A Population-Based Cohort StudyBackground: Radioiodine is used increas...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.